Monitor the August FDA pre-submission meetings for DrugSorb-ATR as the next potential catalyst, but do not anticipate a near-term positive inflection without a clear regulatory or commercial milestone.
Price Chart
Executive Summary
CytoSorbents reported Q2 2026 revenue of $9.6M (flat YoY) and a GAAP net loss of $0.07/share, missing the consensus EPS estimate of -$0.04 by 75%. The company highlighted progress toward operating cash flow breakeven (cash burn reduced to ~$200K ex-restructuring) and outlined four value drivers, but the headline EPS miss and stagnant revenue are the primary takeaway for a $24M market cap company with limited cash runway ($5.9M).
Key Financial Metrics
Key Facts
- Q2 2026 revenue $9.6M, flat YoY vs $9.6M
- GAAP EPS -$0.07 vs consensus -$0.04 (75% miss)
- Adjusted net loss -$0.05/share improved from -$0.06 YoY
- Gross margin improved to 73% from 71% YoY
- Operating loss improved 27% to -$2.6M from -$3.6M YoY
- Cash burn reduced to ~$200K ex-restructuring; total cash $5.9M
- Germany sales declined 24% YoY due to smaller sales force
- Management targeting operating cash flow breakeven in H2 2026
- Two FDA pre-submission meetings scheduled for DrugSorb-ATR in August 2026
Financial Impact
EPS miss of 75% vs consensus on flat revenue; cash runway ~$5.9M at current burn rate
Risk Factors
- Cash runway limited to ~$5.9M; may require dilutive financing before achieving cash flow breakeven
- Germany sales decline of 24% offsets growth in other regions; sales force rebuild may take 6-12 months
- FDA approval for DrugSorb-ATR is uncertain and could face delays or additional data requirements
- Nasdaq listing compliance risk (stockholders' deficit of -$751K)
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-prn-302845431 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 23, 2026 4w ago | 8-K | $4.91 $5.35 | ▲ +8.96% | ▲ +8.27% | $4.85 (−1.22%) |
Aug 6, 2026 11w ago | Press Release | $0.3600 $0.3501 | ▲ +2.75% | ▲ +2.35% | $4.85 (−1247.22%) |
Jun 25, 2026 17w ago | DEFA14A | $0.3620 $0.3600 | ▼ −0.55% | ▼ −1.94% | $4.85 (+1239.78%) |
Jun 16, 2026 19w ago | Insider Cluster | $0.5189 $0.3694 | ▼ −28.81% | ▼ −28.86% | $4.85 (+834.67%) |
Apr 15, 2026 27w ago | 10-K/A | $0.6100 $0.5710 | ▼ −6.39% | ▼ −12.21% | $4.85 (+695.08%) |
Apr 2, 2026 29w ago | 8-K | $0.5830 $0.6100 | ▼ −4.63% | ▲ +5.25% | $4.85 (−731.90%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers